Fintel reports that on November 24, 2025, Barclays maintained coverage of Kura Oncology (NasdaqGS:KURA) with a Overweight recommendation. Analyst Price Forecast Suggests 182.25% Upside As of November ...

Kura Oncology has claimed FDA approval for oral menin inhibitor Komzifti for a form of acute myeloid leukaemia (AML), making it the first direct competitor to Syndax's Revuforj, which launched in the ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Kura Oncology (KURA.O), opens new tab and Japanese partner Kyowa Kirin's (4151.T), opens new tab once-daily pill, Komzifti ...

Kyowa Kirin’s big bet on Kura Oncology has paid off in short order, delivering an FDA approval for a medicine to treat a subset of patients with acute myeloid leukemia. On Thursday, the FDA signed off ...

Kura Oncology (KURA) is forecast to grow revenue at 42.7% per year, far outpacing the US market average of 10.5% per year. However, the company remains unprofitable with losses increasing at a 15.3% ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Kura Oncology Inc. (KURA) on Tuesday reported a loss of $74.1 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 85 ...

Kura Oncology Inc (NASDAQ:KURA) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $41.26 million, and the earnings are expected to come in at -$0.85 ...

Fintel reports that on October 20, 2025, JMP Securities reiterated coverage of Kura Oncology (NasdaqGS:KURA) with a Market Outperform recommendation. Analyst Price Forecast Suggests 175.68% Upside As ...

Kura Revolving Sushi Bar is rolling out three more locations across New Jersey. After a planned opening Sept. 19 at Freehold Raceway Mall in Freehold, the Japan-based chain aims to add outposts at The ...

While it may appear that TWICE’s Chaeyoung mapped out the release of her debut solo album, LIL FANTASY vol.1, to precede the girl group’s 10th anniversary celebration in October, the ...

Kura Oncology is focused on developing targeted therapies for genetically defined cancers. The company’s primary asset is ziftomenib, a menin inhibitor drug designed for genetically defined subtypes ...

SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines ...